Four Companies to Know in Hungary
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Address: Csorsz ut 49-51 H-1124 Budapest,Hungary
Tel: +36 1 577 8200
Web: http://www.astellas.com/worldwide.html
Astellas Pharma Europe the world’s 20 largest pharmaceutical company, belonging to 15 thousand employees worldwide Astellas Pharma Inc. subsidiary. As a young and forward-looking company Astellas aims to improve the quality of life for people around the world, innovative and reliable pharmaceutical products, by providing products.
In 2005, Yamanouchi and Fujisawa merger created Astellas remains committed to the class of the first (‘first-in-class’), and class best (‘best-in-class’) products developed for the key therapeutic areas by combining high R & D and marketing opportunities in the pharmaceutical world market continued growth.
In October 2006, Astellas has launched a company called Vision 2015 management strategy. Declared goal is to világelsőkké within that category (GAL) to become a number of therapeutic areas where further innovation of the patients currently unmet needs can be met. The company’s vision is an integral part in 2008, launched a wide-ranging Changing TOMORROW ™ (‘Change your tomorrow’) campaign, which displays the company’s ability to create a brighter future stakeholders, especially patients.
Significant, ongoing investments in research and development will further strengthen research-based Astellas pharmaceutical company capacity by providing effective medicines for patients worldwide, and continues to doctors and trusted partner of network deployment.
In Europe the main strengths of the Astella organ transplantation, urology, dermatology and anti-infective agents and the therapeutic areas of pain prevail. In addition, Astellas aims to develop a gyógyszerportfóliót the needs of cancer patients.
Astellas Pharma Europe Ltd. is based in Staines near London, and operates sales subsidiaries throughout Europe and the CIS states and South Africa. Astellas Pharma International, as well as licensors and distributors, the company responsible for the Middle East and Africa sales as well.
Geninax® : an oral new-type quinolone antibacterial agent
Celecox® : the selective COX-2 lnhibitor
Lipitor® : a treatment for hypercholesterolemia
Micardis® : a treatment for hypertension
Gaster® : a treatment for peptic ulcers and gastritis
Luvox® : an antidepressant
Myslee® : a hypnotic
Cefzon® : an oral cephalosporin
Seroquel® : an antipsychotic agent
Dorner® : a treatment for chronic arterial occlusion
Nasea® : a 5-HT3 (receptor) antagonist
Targocid® : a glycopeptide antibiotic
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Dr. Zsuzsanna Fürst, President of the Ethics Committee for Clinical Pharmacology, elaborates on the role and activities of the ethics committee, shares her insights on structural framework of the application…
Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of…
Irisz Lippai-Nagy, CEO of AmCham Hungary, shares insights on the drivers contributing to economic growth in Hungary, recent policies and reforms, the role of the association, and policy recommendations to…
Oliver Strommer, newly appointed executive director of the British Chamber of Commerce in Hungary (BCCH), introduces the Chamber and its refocused aim of becoming a more dynamic player in business…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to…
Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in…
Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that…
See our Cookie Privacy Policy Here
